山东沃华医药科技股份有限公司 2025年度股东会决议公告

Meeting Overview - The shareholders' meeting was convened by the company's board of directors, combining on-site voting and online voting [2][3] - The meeting took place on February 9, 2026, with the on-site meeting starting at 14:00 and online voting available from 9:15 to 15:00 [2][3] Attendance - A total of 244 shareholders attended the meeting, representing 300,230,158 shares, which is 52.0141% of the total voting shares [4] - Among them, 4 shareholders attended on-site, representing 297,938,963 shares (51.6171%), while 240 shareholders participated via online voting, representing 2,291,195 shares (0.3969%) [5][6] Proposals Reviewed and Approved - The following proposals were reviewed and approved during the meeting: - The 2025 Board of Directors' Work Report was approved with 99.9150% of votes in favor [11] - The 2025 Financial Settlement Report was approved with 99.9073% of votes in favor [12] - The 2025 Profit Distribution Plan was approved with 99.9093% of votes in favor, with 89.0420% of small investors voting in favor [13] - The 2025 Annual Report and its summary were approved with 99.9086% of votes in favor [14] - The proposal to reappoint the accounting firm Zhongxi CPA for the 2026 financial audit was approved with 99.8843% of votes in favor, with 86.0147% of small investors voting in favor [15] - The proposal regarding the restructuring of production operations and related transactions was approved with 97.1021% of votes in favor [16][18] Independent Directors' Report - Independent directors submitted their annual performance report, detailing their attendance at board meetings, independent opinions, and suggestions for the company's development [19] Legal Opinions - The meeting was witnessed by lawyers from Beijing Xinghe Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [19]